แหล่งอ้างอิงเพิ่มเติม 15. Burstein SH. Ajulemic acid: potential treatment for chronic inflammation. Pharmacology research & perspectives. 2018 Apr;6(2):e00394. 16. Callaghan RC, Allebeck P, Akre O, McGlynn KA, Sidorchuk A. Cannabis use and incidence of testicular cancer: a 42-year follow-up of Swedish men between 1970 and 2011. Cancer Epidemiology and Prevention Biomarkers. 2017 Nov 1;26(11):1644-52. 17. Campbell G, Hall WD, Peacock A, Lintzeris N, Bruno R, Larance B, Nielsen S, Cohen M, Chan G, Mattick RP, Blyth F. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. The Lancet Public Health. 2018 Jul 1;3(7):e341-50. 18. CYR, Claude, et al. Cannabis in palliative care: current challenges and practical recommendations. Ann Palliat Med, 2018, 7.4: 463-477. 19. Dariš B, Verboten MT, Knez Ž, Ferk P. Cannabinoids in cancer treatment: Therapeutic potential and legislation. Bosnian journal of basic medical sciences. 2019 Feb;19(1):14. 20. Dos Santos RG, Hallak JE, Leite JP, Zuardi AW, Crippa JA. Phytocannabinoids and epilepsy. Journal of clinical pharmacy and therapeutics. 2015 Apr;40(2):135-43. 21. Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. Journal of psychopharmacology. 2013 Jan;27(1):19-27. 22. Epidiolex - cannabidiol solution. (2020). dailymed.nlm.nih.gov/dailymed/druglnfo.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec 23. Esposito G, Filippis DD, Cirillo C, Iuvone T, Capoccia E, Scuderi C, Steardo A, Cuomo R, Steardo L. Cannabidiol in inflammatory bowel diseases: a brief overview. Phytotherapy Research. 2013 May;27(5):633-6. 24. FDA U. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). US Food & Drug Administration. 2020:18. 25. Fine PG, Rosenfeld MJ. The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides medical journal. 2013 Oct;4(4). 26. Friedman D, Sirven JI. Historical perspective on the medical use of cannabis for epilepsy: ancient times to the 1980s. Epilepsy & Behavior. 2017 May 1;70:298-301. 27. FRIEDMAN, Daniel; DEVINSKY, Orrin. Cannabinoids in the treatment of epilepsy. New England Journal of Medicine, 2015, 373.11: 1048-1058. 28. Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis and cannabinoid research. 2017 Jun 1;2(1):139-54. 29. Jett J, Stone E, Warren G, Cummings KM. Cannabis use, lung cancer, and related issues. Journal of Thoracic Oncology. 2018 Apr 1;13(4):480-7. 30. Lim K, See YM, Lee J. A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clinical Psychopharmacology and Neuroscience. 2017 Nov;15(4):301. 31. Lochte BC, Beletsky A, Samuel NK, Grant I. The use of cannabis for headache disorders. Cannabis and cannabinoid research. 2017 Apr 1;2(1):61-71. 32. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. European journal of internal medicine. 2018 Mar 1;49:12-9. 33. McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. American Journal of Psychiatry. 2018 Mar 1;175(3):225-31. 34. Meier MH, Caspi A, Cerdá M, Hancox RJ, Harrington H, Houts R, Poulton R, Ramrakha S, Thomson WM, Moffitt TE. Associations between cannabis use and physical health problems in early midlife: a longitudinal comparison of persistent cannabis vs tobacco users. JAMA psychiatry. 2016 Jul 1;73(7):731-40. 35. Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: a complex picture. Phytocannabinoids. 2017:103-31. 36. Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. The British Journal of Psychiatry. 2010 Oct;197(4):285-90. 37. National Academies of Sciences, Engineering, and Medicine. "The health effects of cannabis and cannabinoids: Committee’s conclusions." (2017). 38. National Health Service (NHS). " Cannabis: the facts -Healthy body" National Health Service (NHS), 30 Dec. 2020, www.nhs.uk/live-well/healthy-body/cannabis-the-facts/?tabname=body Accessed 5 Jun. 2021. 39. National Institute on Drug Abuse (NIDA). "Is marijuana addictive?." National Institute on Drug Abuse, 13 Apr. 2021, www.drugabuse.gov/publications/research-reports/marijuana/marijuana-addictive Accessed 5 Jun. 2021. 40. National Institute on Drug Abuse (NIDA). "Marijuana DrugFacts." National Institute on Drug Abuse, 24 Dec. 2019, www.drugabuse.gov/publications/drugfacts/marijuana Accessed 5 Jun. 2021. 41. National Institute on Drug Abuse (NIDA). "What is the scope of marijuana use in the United States?." National Institute on Drug Abuse, 20 Apr. 2021, www.drugabuse.gov/publications/research-reports/marijuana/what-scope-marijuana-use-in-united-states Accessed 5 Jun. 2021. 42. Nugent SM, Morasco BJ, O'Neil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu'apuaka M, Paynter R, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Annals of internal medicine. 2017 Sep 5;167(5):319-31. 43. Phillips JA, Holland MG, Baldwin DD, Gifford-Meuleveld L, Mueller KL, Perkison B, Upfal M, Dreger M. Marijuana in the workplace: guidance for occupational health professionals and employers: joint guidance statement of the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine. Workplace health & safety. 2015 Apr;63(4):139-64. 44. Schleider LB, Mechoulam R, Lederman V, Hilou M, Lencovsky O, Betzalel O, Shbiro L, Novack V. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. European journal of internal medicine. 2018 Mar 1;49:37-43. 45. Shannon S, Opila-Lehman J. Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. The Permanente Journal. 2016;20(4). 46. Stith SS, Vigil JM, Brockelman F, Keeling K, Hall B. The association between cannabis product characteristics and symptom relief. Scientific reports. 2019 Feb 25;9(1):1-8. 47. Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P, Teare MD, Woll PJ, Orlow I, Cox B, Cannabis and Respiratory Disease Research Group of New Zealand, Brhane Y. Cannabis smoking and lung cancer risk: Pooled analysis in the I nternational L ung C ancer C onsortium. International journal of cancer. 2015 Feb 15;136(4):894-903. 48. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by Δ 9-THC in normal subjects. Psychopharmacology. 1982 Mar;76(3):245-50.